Shuli Innovation Secures Hundreds of Millions in Series C Funding to Advance Non-Invasive Brain-Computer Interface Solutions

Recently, Arfysica Innovation, a brain-computer interface technology company, has completed its C-round financing of several hundred million RMB. This round of financing was jointly invested by multiple institutions including Daohe Capital, Oriental Hengxin, and Xinding Rongsheng Capital Management Co., Ltd, as well as existing shareholders.

The rapid completion of a new round of financing represents not only the capital market's high recognition of Arfysica Innovation's core technical strength and commercial closed-loop capabilities but also injects crucial momentum for the company’s next strategic upgrade. With the empowerment of capital, Arfysica Innovation will continue to drive generational leaps in brain-computer interface technology, deepen diverse industrial applications, and build an innovative full-chain ecosystem for brain-computer interfaces across multiple scenarios.

Arfysica Innovation, as the leader in the non-invasive brain-computer interface sector, possesses comprehensive capabilities in "full-stack self-research + clinical transformation + large-scale production." Its product portfolio extensively covers three major areas: limb motor dysfunction caused by central nervous system injury, consciousness and cognitive disorders, and neurodevelopmental disorders. The series of products have been applied in the neurosurgery, neurology, rehabilitation, and pediatrics departments of numerous well-known tertiary hospitals in China.